Add Tickers. No Saved Watchlists Create a list of the investments you want to track. Create Watchlist …or learn more. Uh oh Something went wrong while loading Watchlist. Go to Watchlist. No Recent Tickers Visit a quote page and your recently viewed tickers will be displayed here. Search Tickers. MarketWatch Dow Jones. ET by Barron's. ET by MarketWatch. ET by Val Brickates Kennedy. Premium U. ET by Michael Ashbaugh. ET by Steve Gelsi.
The Amyris stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
A break-up above any of these levels will issue buy signals. This stock may move very much during the day volatility and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". For the last week, the stock has had a daily average volatility of Amyris is oversold on RSI14 Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.
Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set. Amyris holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
The predicted opening price is based on yesterday's movements between high, low, and the closing price. Click to get the best stock tips daily for free!
Amyris, Inc. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons. Reporting Quality M-Score. Possible Manipulator. Amyris Inc generated a negative expected return over the last 90 days. Amyris Inc has high historical volatility and very poor performance.
Amyris Inc has a very high chance of going through financial distress in the upcoming years. The company reported the previous year's revenue of Amyris Inc has a poor financial position based on the latest SEC disclosures.
Roughly Latest headline from www. Capital Expenditure. Depreciation Amortization and Accretion. Issuance Purchase of Equity Shares. Issuance Repayment of Debt Securities. Net Cash Flow from Financing. Net Cash Flow from Investing. Net Cash Flow from Operations. Effect of Exchange Rate Changes on Cash. Share Based Compensation. Compare Amyris to competition. Return On Equity. Return On Asset. Profit Margin. Operating Margin. Shares Outstanding.
Shares Owned by Insiders. Shares Owned by Institutions. Number of Shares Shorted. Price to Earning. Price to Book. Price to Sales. Gross Profit. Net Income. Cash and Equivalents. Cash per Share. Total Debt. Debt to Equity. Current Ratio. Book Value Per Share. Cash Flow from Operations. Short Ratio. Earnings Per Share. Price to Earnings To Growth. Number of Employees.
Market Capitalization. Total Asset. Retained Earnings. To solve this problem, Amyris markets its own consumer brands like the Biossance brand of high-squalene-content skin moisturizers for adults and the Pipette brand of baby skincare products.
Before Amyris came along, squalene for skincare products was traditionally sourced from sharks a few ounces at a time. A consumer base increasingly aware of the environmental impact their purchases make are big fans of Amyris' products.
Instead of killing sharks, Amyris just feeds sugarcane to a proprietary strain of yeast that produces squalene in big fermentation vats. In , though, this life-science company will probably be able to report positive earnings without selling off any assets.
Amyris currently relies on Royal DSM and other partners for manufacturing, but not for much longer. The company's invested heavily into a new ingredient plant in Brazil. The COVID pandemic isn't helping with timelines, but Amyris thinks it can get its first fully owned manufacturing facility up and running before the end of the year.
The company's bottom line will benefit from expanding gross margins and significantly lower interest expenses. Zymergen's recent implosion doesn't necessarily mean it can't begin producing profits for investors, but it's going to be at least a few years before the company can tell you when. Amyris is already on the cusp of sustainable profitability with success from the Biossance brand alone.
With a handful of younger brands with Biossance-sized potential launching now, it's just a matter of time before this stock starts getting the attention it deserves. Discounted offers are only available to new members. Stock Advisor will renew at the then current list price.
0コメント